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Abstract 
 
Objective: Atherosclerosis, the cause of 50% of deaths in westernised societies, is widely 
regarded as a chronic vascular inflammatory disease. Vascular smooth muscle cell (VSMC) 
inflammatory activation in response to local pro-inflammatory stimuli contributes to disease 
progression and is a pervasive feature in developing atherosclerotic plaques. Therefore, it is 
of considerable therapeutic importance to identify mechanisms that regulate the VSMC 
inflammatory response. 
Approach and Results: We report that myocardin, a powerful myogenic transcriptional 
coactivator, negatively regulates VSMC inflammatory activation and vascular disease. 
Myocardin levels are reduced during atherosclerosis, in association with phenotypic 
switching of smooth muscle cells. Myocardin deficiency accelerates atherogenesis in 
hypercholesterolemic ApoE
-/-
 mice. Conversely, increased myocardin expression potently 
abrogates the induction of an array of inflammatory cytokines, chemokines and adhesion 
molecules in VSMCs. Expression of myocardin in VSMCs reduces lipid uptake, macrophage 
interaction, chemotaxis and macrophage-endothelial tethering in vitro, and attenuates 
monocyte accumulation within developing lesions in vivo. These results demonstrate that 
endogenous levels of myocardin are a critical regulator of vessel inflammation. 
Conclusions: We propose myocardin as a guardian of the contractile, non-inflammatory 
VSMC phenotype, with loss of myocardin representing a critical permissive step in the 
process of phenotypic transition and inflammatory activation, at the onset of vascular disease. 
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Introduction 
 
Cardiovascular diseases are the cause of substantial mortality and morbidity across the 
Western and, increasingly, the developing worlds.
1,2
 Chronic inflammation is a pathological 
process that represents a common, critical hallmark in the development of multiple occlusive 
vascular diseases including transplant vasculopathy, interventional restenosis and 
atherosclerosis.
3,4
 Vascular smooth muscle cells (VSMCs) undergo a unique, coordinated 
morphological and functional transition between contractile and synthetic states in injury and 
disease.
5
 Inflammatory activation of medial VSMCs refers to the attainment of a phenotypic 
state in which cells secrete a diverse range of pro-inflammatory mediators such as cytokines, 
chemokines and adhesion molecules, in response to a variety of signals in the surrounding 
milieu. VSMC inflammatory activation contributes to vessel pathophysiology, vascular 
disease progression and ultimately, adverse clinical outcome.
6,7 
Therefore, it is of 
considerable therapeutic importance to identify mechanisms that regulate the VSMC 
inflammatory response. 
Myocardin (Myocd) is a potent myogenic coactivator, expressed specifically in contractile 
smooth and cardiac muscle tissues in adulthood, and respective progenitor cells during 
embryonic development.
8,9,10,11
 Myocardin associates strongly with serum response factor 
(SRF) and stabilizes binding at the degenerate CC(A/T-rich)6GG (CArG) cis-elements of all 
known CArG-dependent SMC marker genes.
5,12
 Myocardin homozygous-null (Myocd
-/-
) 
mice exhibit impaired SMC development and die at embryonic day 10.5,
13 
although Myocd
-/-
 
embryonic stem cells retain some capacity to differentiate into SMC lineages in vitro and in 
vivo.
14,15
 However, myocardin-deficient VSMCs show reduced expression of contractile 
apparatus and exhibit ultrastructural features associated with the synthetic phenotype.
16
 
A growing number of studies report a correlation between vascular injury or disease 
progression, and reduced myocardin expression
17,18,19,20,21 
or alternative splicing of myocardin 
pre-mRNA.
22
 Furthermore, Lovren and colleagues
23
 observed that attenuated lesion 
development following miR-145 administration to VSMCs in hypercholesterolemic ApoE
-/-
 
mice coincided with increased myocardin levels. However, despite previous in vitro evidence 
that myocardin negatively regulates VSMC proliferation,
9,11,24
 this association is consistently 
regarded as secondary to disease progression, and myocardin is referred to purely as a marker 
of SMC contractile gene expression. Recently, we set out to address this shortcoming, and 
identified myocardin as a critical regulator of the vessel injury response in vivo.
25
 Re-
expression of myocardin suppressed neointima formation in murine carotid arteries, while 
myocardin-heterozygous-null (Myocd
+/-
) mice displayed augmented neointima formation 
with increased VSMC migration and proliferation. Utilising both loss and gain-of-function 
models, in vitro and in vivo, we now demonstrate that myocardin is a central negative 
regulator of VSMC inflammatory activation and associated vascular disease. 
 
 
Materials and Methods 
 
Materials and Methods are available in the online-only Data Supplement. 
 
 
Results 
 
Myocardin expression is reduced in VSMCs at the onset of vascular disease 
Studies in mice and swine have shown that expression of myocardin in the vascular wall is 
decreased following injury and in atherosclerosis, associated with reduced SMC marker gene 
expression.
17,18,19,20
 To examine the reproducibility and temporal dynamics of these 
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observations in an established model of atherosclerosis, we examined myocardin expression 
following placement of a non-constrictive collar around the common carotid arteries of high 
fat diet-fed LDLR
-/- 
mice.
26,27
 In this model, significant neointimal lesions develop by 6 
weeks following collar placement. A marked downregulation of myocardin RNA expression 
was confirmed two weeks post-surgery (P<0.01, Figure 1A), accompanied by concomitant 
fall in SMC marker gene expression (Figure 1B). These data demonstrate that 
downregulation of myocardin is an early and consistent feature of vascular disease, as in 
vascular injury.
25
 Subsequent analysis of healthy aortic and diseased carotid human artery 
samples confirmed that myocardin expression is similarly reduced in diseased human vessels 
compared to healthy controls (P<0.05; Figure 1C). Differential myocardin expression is 
maintained in their respective human artery VSMC cultures (Figure 1D), indicating that the 
change is intrinsic to VSMCs, and not attributable to differential VSMC numbers relative to 
other cell types within healthy and diseased vessel walls. 
 
Myocardin deficiency is causal for accelerated vascular disease 
Myocd
+/-
 mice have reduced aortic myocardin expression, but similar levels of myocardin-
like transcription factors Mkl1 and Mkl2, compared to wild-type littermates (Figure IA of the 
online only Data Supplement).
25
 These mice show a novel phenotype of augmented 
neointima formation following vascular injury, with increased VSMC migration and 
proliferation.
25
 To determine whether reduced myocardin expression in VSMCs represents a 
critical permissive step in early vascular disease progression, Myocd
+/-
 mice were crossed 
onto an ApoE
-/-
 background.
28
 Mice were then administered high fat diet for 8 weeks, before 
analysis of atherosclerotic lesion development in the aortic root. A relatively short period of 
fat-feeding was selected to visualise early stages of vascular disease, whereby accelerated 
progression could present most clearly. ApoE
-/-
.Myocd
+/-
 mice exhibited a significant, close 
to 50% mean increase in plaque area, compared to ApoE
-/-
.Myocd
+/+
 (wild type; WT) 
littermate controls (P=0.05; Figure 1E-G). Total medial area was unchanged between groups. 
A complete set of aortic root cross-section images analysed in this study is provided in Figure 
IIA of the online-only Data Supplement. A second independent study further substantiated 
these findings, showing a 25% mean increase in oil red O staining of lipid rich regions in the 
aortic root of ApoE
-/-
.Myocd
+/-
 mice compared to ApoE
-/-
.Myocd
+/+
 controls (P=0.04, Figure 
1G-H). Data from these loss-of-function studies provide the first compelling evidence that 
endogenous levels of myocardin negatively regulate the progress of atherosclerosis in vivo. 
 
Myocardin-deficient SMCs exhibit increased potential for inflammatory activation  
VSMC inflammatory activation contributes to the propagation of inflammation in the 
developing lesion, and to the progression of vascular disease. We hypothesized that 
myocardin may reduce vascular disease through suppression of VSMC phenotypic transition 
and inflammatory activation. It was reasoned that reduced VSMC inflammatory activation 
within a developing lesion would manifest in reduced inflammatory mediator production and 
reduced leukocyte infiltration. Indeed, increased numbers of Lamp2 (Mac3)-positive 
macrophage-like cells were observed in lesions of Myocd
+/-
 mice compared with WT 
littermate controls (P<0.01; Figure 2A and 2B). IgG negative controls confirmed the 
specificity of Lamp2 immunostaining in the aorta, while immunostaining against an 
alternative macrophage cell surface marker, CD68, recapitulated the Lamp2 staining results 
(Figures III and IV of the online-only Data Supplement).While we consider these cells as 
macrophages of circulating leukocyte origin, we do not exclude the possibility that a 
proportion are VSMCs that have downregulated smooth muscle marker gene expression, 
upregulated macrophage markers and assumed macrophage-like morphology.
29,30
 Consistent 
with increased leukocyte accumulation, we found significantly greater levels of circulating 
chemokine monocyte chemotactic protein-1 (CCL2) in Myocd
+/-
 animals compared to WT 
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littermates 4 weeks after initiation of the high fat diet (Figure 2C). Immunostaining revealed 
similarly increased levels of CCL2 in the aortic lesions of Myocd
+/-
 mice, compared to WT 
littermate controls (Figure V of the online-only Data Supplement). 
Analysis of aortic root tissue harvested after 1-week high fat diet revealed early differences in 
inflammatory gene expression between Myocd
+/-
 and WT mice (Figure 2D). Levels of the 
atherogenic cytokine interleukin (Il)-6 were significantly increased in aortic roots of Myocd
+/-
 
mice (P<0.05).
31
 We also found increased expression of pro-inflammatory 
CCAAT/enhancer-binding protein (C/Ebp) transcription factors Cebpb and Cebpd in 
Myocd
+/-
 aorta. No significant change in Ccl2 expression was observed, possibly reflecting 
specific temporal regulation of inflammatory gene expression, or clouding of differential 
signal from VSMCs by other cell types present in whole aortic root tissue. 
To test whether increased inflammatory activation and leukocyte infiltration may indeed be 
driven specifically by myocardin-deficient VSMCs, medial aortic VSMCs were cultured 
from Myocd
+/-
 mice and WT littermate controls. These cells were then exposed to varying 
concentrations of the pro-inflammatory cytokine IL-1β, which has been shown to elicit an 
inflammatory phenotypic state in VSMCs.
32
 IL-1β-induced IL-6 release is an established 
indicator of VSMC inflammatory activation.
33
 IL-1β induced a marked upregulation of Il-6 
and Ccl2 mRNA, and levels were consistently and significantly higher in VSMCs derived 
from Myocd
+/-
 mice (Figure 2E and 2F). Furthermore, the mRNA expression of Cebpb and 
Cebpd was similarly increased in myocardin-deficient VSMCs (Figure 2G and 2H).  
Il-6 and Ccl2 strongly recruit macrophages and monocytes to developing lesions, regulate the 
local expression of adhesion molecules, cytokines and the pro-coagulant tissue factor, and 
propagate inflammation in the nascent lesion.
7,34,35
 CEBPB and CEBPD bind at the promoters 
of multiple inflammatory response genes, including Il-6 and Ccl2, and synergistically 
upregulate and sustain gene expression following inflammatory stimulation.
36,37,38
 
Upregulation of Il-6, Ccl2 and Cebp factors in myocardin deficient VSMC is therefore highly 
suggestive of fundamental transition towards a pro-inflammatory state.  Enhanced VSMC 
inflammatory activation in myocardin-deficient VSMCs thereby provides an endogenous 
mechanism by which accelerated vascular disease may proceed.  
 
Myocardin deficiency amplifies inflammatory responses in human VSMC 
To test the relevance of myocardin deficiency in human disease, human coronary artery 
VSMC (HCASMC) were grown and transfected with myocardin-specific small interfering 
RNA (siRNA). A reduction of roughly 50% myocardin expression was observed compared to 
controls (Figure VI of the online-only Data Supplement). Consistent with observations in 
mouse VSMCs, reduced myocardin expression in HCASMC caused marked increases in IL-
1β-induced IL6 and CCL2 production (P<0.001), both in terms of mRNA expression and 
protein secretion, as determined by enzyme-linked immunosorbence assay (ELISA) (Figure 
3A-3C). Consistent with data from the Myocd
+/-
 aortas, CEBPB and CEBPD expression were 
also increased in myocardin-deficient HCASMC (P<0.001 and P<0.01, respectively). 
Importantly, inhibition of CEBPB and CEBPD expression in the presence of myocardin 
deficiency was able to partially reverse the increase in inflammatory IL-6 and CCL2 marker 
production (Figure 3B and3C). This finding is in line with our prior observation that siRNA-
mediated inhibition of CebpB and CebpD can suppress IL-1β-induced expression of 
inflammatory mediators such as Il-6 in rat aortic VSMC (RASMC) (data not shown). These 
data are thus consistent with our previous findings and support the relevance of myocardin in 
regulating vascular inflammation in human disease, regulation that may occur at least in part 
through the inhibition of intermediate inflammatory pathway mediators such as CEBPB and 
CEBPD. 
 
Myocardin expression suppresses inflammatory activation in cultured VSMC 
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We next set out to test whether, conversely, augmented myocardin expression in VSMCs 
protects against the transition towards the inflammatory phenotype. Rat aortic VSMC, which 
grow reproducibly in culture and express low levels of endogenous myocardin, were treated 
with adenoviral expression constructs encoding myocardin (Ad.Myocd), or β-galactosidase 
(Ad.LacZ) and Myocd-DN (Ad.Myocd-DN) negative expression controls. Myocd-DN 
encodes a truncated form of myocardin that lacks the C-terminal transcription activating 
domain.
8
 Efficient expression of relevant constructs was confirmed by Western Blotting 
(Figure IC-ID of the online-only Data Supplement). Myocardin and contractile SMC marker 
gene expression was significantly upregulated following Ad.Myocd administration (Figure 
VII of the online-only Data Supplement). Ad.Myocd-DN exerted no discernible dominant-
negative effect
39
, likely due to low endogenous levels of myocardin in cultured rat VSMC.
9
 
Due to closer molecular similarity to Ad.Myocd, Ad.Myocd-DN was therefore employed as 
the optimal negative expression control for in vitro studies. Complete datasets containing no-
virus and Ad.LacZ controls are shown in Figure VIII of the online-only Data Supplement. 
The inhibition of lipopolysaccharide (LPS)-induced tumour necrosis factor (TNF-α) and IL-6 
production in aortic VSMC by myocardin has been reported previously.
24
 Given the 
complexity of the atherogenic inflammatory process,
7
 we elected to expand on this finding to 
investigate the effect of myocardin on the IL-1β-stimulated expression of a selection of 
cytokines, chemokines and adhesion molecules with documented roles in atherosclerosis. 
Real time RT-PCR expression data is presented in heat-map format for ease of visualisation 
(Figure 3D) and in full as bar charts (Figure VIII of the online-only Data Supplement). 
Expression of myocardin was found to strongly and reproducibly suppress the IL-1β-induced 
expression of a diverse range of pro-inflammatory factors including IL-6, CCL-2, NOS2, 
CXCL2, CX3CL1, VCAM-1 and CSF-1. Notably, suppression was not universal, with 
ICAM-1 apparently unaffected, and CSF-3 significantly upregulated in the presence of 
myocardin. Myocardin also significantly reduced the expression of inflammation-mediating 
IL-1 receptors IL-1R1 and IL-1R2, the IL-6 receptor IL-6R, the TNFα receptor TNFRSF1A 
and the oxidized low-density lipoprotein scavenger receptor OLR-1, which is consistent with 
reduced potential for inflammatory activation. Furthermore, myocardin expression 
upregulated the putative anti-inflammatory cytokine IL-19,
40,41
 and two members of the 
immunosuppressive suppressor of cytokine signalling (SOCS) family, SOCS-2 and SOCS-
6.
42
 Given our previous finding of  increased inflammatory activation in HCASMC treated 
with MYOCD siRNA, we tested whether Ad.Myocd-DN might exhibit a dominant-effect in 
this setting of potentially higher endogenous myocardin. However, no significant effect was 
observed, although there was a trend towards decreased expression of the smooth muscle 
marker gene MYH11 in the presence of Ad.Myocd-DN (Figure IX of the online-only Data 
Supplement). Speculatively, the truncated mouse Myocd encoded in Ad.Myocd-DN may not 
compete well with endogenous human Myocd in HCASMC, except possibly at particularly 
specific, myocardin-sensitive promoters or enhancer elements. Mouse Myocd encoded by 
Ad.Myocd was, on the other hand, able to potently suppress IL-1β-induced inflammatory 
marker gene expression and IL-6/CCL2 secretion in HCASMC (Figure X of the online-only 
Data supplement). 
Production of inflammatory factors in VSMCs is controlled pre-translationally, typically at 
the level of transcription.
7,43
 Analysis of cell supernatants by ELISA confirmed a marked 
induction of IL-6 and CCL2 protein secretion from IL-1β-stimulated rat VSMCs, which was 
robustly abrogated following administration of Ad.Myocd (P<0.001; Figure 3E and 3F). IL-6 
release in response to stimulation by TNF-α and LPS was also suppressed by myocardin 
(Figure XI of the online-only Data Supplement). Increasing Ad.Myocd multiplicity of 
infection (MOI) resulted in a roughly linear decrease in CCL2 secretion (Figure XIE of the 
online-only Data Supplement). Consistent with previous results, mRNA expression of Cebpb 
and Cebpd was induced by inflammatory stimulation but strongly repressed in the presence 
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of myocardin (P<0.05; Figure 3G and 3H). Reduced abundance of both active isoforms of 
CEBPB, LAP* and LAP,
44
 and CEBPD, were observed by Western blotting (Figure 3I). 
Furthermore, analysis of the Il6 promoter by chromatin immunoprecipitation (ChIP) revealed 
a marked increase in CEBPB protein binding following IL-1 stimulation, which was 
abrogated in the presence of Myocd expression (Figure 3J). However, no significant changes 
in binding of CEBPB to the Ccl2 promoter were detected. Binding of CEBPD was also not 
detected, despite analysis of multiple putative binding regions at the Ccl2 promoter (Figure 
XII of the online-only data supplement), although this may be attributable to a paucity of 
ChIP-grade antibodies available to target CEBPD. 
Taken together, these data demonstrate that myocardin expression can actively and 
specifically suppress multiple facets of inflammatory activation in cultured VSMC, including 
the intracellular inflammatory pathway mediators CEBPB and CEBPD and furthermore, 
stimulate one or more distinct anti-inflammatory responses. 
 
Myocardin suppresses lipid uptake in human VSMC 
To corroborate previous in vitro data, further studies were performed to test the functional 
relevance of reduced VSMC inflammatory activation in the presence of increased myocardin 
expression. We previously noted that myocardin expression causes downregulation of the 
scavenger receptor OLR-1 (Figure 3D). OLR-1 mediates oxidised low-density lipoprotein 
(oxLDL) uptake in VSMCs, contributing to foam cell formation and progression of vascular 
disease.
45
 To examine whether OLR-1 downregulation translated functionally to reduced 
lipid uptake, HCASMC were incubated with fluorescent dil-labelled oxLDL. A marked, 
significant reduction in dil-oxLDL uptake in Ad.Myocd-treated VSMCs was measured at 
both two and three hours post addition, versus controls (P<0.01; Figure 4). Myocardin-
induced OLR-1 downregulation in VSMC is thereby consistent with a functional reduction in 
pathological cellular lipid uptake. 
 
Myocardin expression in VSMC suppresses macrophage chemotaxis, adhesion and lipid 
uptake in vitro. 
Activated VSMCs are known to contribute to the recruitment and maturation of circulating 
leukocytes, and subsequent propagation of lesion inflammation, through the secretion of a 
diverse assortment of chemokines including CCL2, CSF-1, IL-6 and CX3CL1.
7,46,47
 We 
reasoned that myocardin expression in VSMCs would attenuate the leukocyte chemotactic 
response through downregulation of many such factors. To test this, a trans-well migration 
assay model was adopted, wherein cultured VSMC were assessed for their ability to induce 
migration of fluorescently labelled macrophages through a trans-well insert membrane 
(Figure XIII  of the online-only Data Supplement). Pre-stimulation of control rat VSMCs 
with IL-1β produced a marked induction of macrophage chemotaxis across the trans-well 
insert membrane, and this migration was significantly attenuated by myocardin expression in 
the VSMCs (P<0.05; Figure 5A). In a separate experiment, adhesion of macrophages 
following incubation with a rat VSMC monolayer was similarly quantified. Lesion-dwelling 
macrophages are known to interact with resident VSMCs, providing synergistic enhancement 
of pro-inflammatory responses such as IL-6 and CCL2 production.
48
 Again, macrophage 
adherence was increased when VSMCs were pre-treated with IL-1β, but this increase was 
strongly abrogated in VSMCs that had been previously administered with Ad.Myocd 
(P<0.01; Figure 5B). This is consistent with our observation that myocardin expression 
reduces the abundance of VSMC surface adhesion molecules such as CX3CL1 and VCAM. 
Another critical interaction in early atherogenesis is the tethering of circulating monocytes to 
activated endothelial cells (ECs) at the vessel wall.
49
 While ECs do not themselves express 
myocardin, ECs and underlying VSMCs conceivably participate in extensive inflammatory 
cross-talk. Thus, reduced VSMC inflammatory activation could translate to reduced EC 
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stimulation and reduced EC-leukocyte tethering. Accordingly, conditioned media were 
collected from pre-treated rat VSMCs, and used to pre-stimulate EC monolayers. 
Macrophage adhesion to the monolayers was then quantified as previously (Figure XIIB of 
the online-only Data Supplement). Results demonstrated a small but significant increase in 
macrophage tethering to ECs treated with conditioned media from IL-1β-stimulated VSMCs. 
This increase was not seen in ECs treated with conditioned media from Ad.Myocd-treated 
VSMCs (P<0.05; Figure 5C). In a final in vitro functional assay, conditioned media from pre-
treated rat VSMCs was tested for its ability to influence lipid uptake in macrophages, which 
represents another central process in atherosclerotic lesion progression.
4
 Macrophages were 
maintained in the conditioned media and then assayed for uptake of fluorescent Dil-labelled 
Ac-LDL. Lipid uptake was significantly increased following exposure to conditioned media 
from IL-1β-treated VSMCs, but this increase was completely abrogated when the VSMCs 
had been treated with Ad.Myocd (Figure 5D and 5E). In order to validate the relevance of 
these findings across species boundaries, macrophage chemotaxis and interaction assays were 
further repeated with HCASMC in place of rat VSMC, and the same myocardin-mediated 
suppression of both processes was consistently observed (Figure XIVA and XIVB of the 
online-only Data Supplement). Therefore, myocardin-induced repression of VSMC 
inflammatory activation may functionally regulate several key processes in atherogenesis, 
including EC-leukocyte tethering, leukocyte chemotaxis, VSMC-leukocyte interaction and 
macrophage lipid uptake. 
 
Myocardin overexpression reduces neointimal response and macrophage accumulation 
in vivo. 
Transluminal wire injury is an established procedure to induce endothelial denudation and 
vascular injury response in mouse carotid arteries. Performing transluminal wire injury in 
atherosclerosis-prone ApoE
-/-
, hypercholesterolemic mice
50
 is further known to induce the 
formation of a neointima that shares numerous characteristic features with developing 
atherosclerotic lesions, including significant macrophage infiltration and even the appearance 
of cholesterol crystals. This model was therefore adopted as a means to study the functional 
effects of increased myocardin expression in VSMCs, during a vascular disease-like 
situation, in vivo. Wire injury of left common carotids was performed and Ad.LacZ control or 
Ad.Myocd adenoviruses were applied intra-luminally. Efficient transduction and elevated 
expression of Myocd and SMC marker genes following Ad.Myocd administration is 
documented in our recent report,
25
 since to reduce animal usage, both studies utilised sections 
from the same mice. Ad.LacZ permeation and subsequent beta-galactosidase expression 
throughout the vessel media was demonstrated and is reproduced here in Figure IB of the 
online-only Data Supplement. We hypothesised here that administration of Ad.Myocd would 
reduce macrophage accumulation at the site of carotid injury. Formation of a Lamp2-positive 
macrophage-rich neointima was evident in both groups, but appeared attenuated in arteries 
administered with Ad.Myocd. Manual quantification of Lamp2-positive cells in each section 
confirmed that application of Ad.Myocd to VSMCs at the site of injury had significantly 
suppressed macrophage accumulation at the site of vascular injury by two-fold (P<0.05; 
Figure 6A and 6B). This result is consistent with the previous in vitro data. These studies 
therefore provide strong in vivo evidence to support the conclusion that increased expression 
of myocardin in VSMC is functionally protective against the onset of inflammatory vascular 
disease. 
 
 
Discussion 
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Atherosclerosis is a multi-factorial, chronic inflammatory disease of the vasculature. The 
development of this condition involves a complex interplay between cells resident in the 
vascular wall, and infiltrating cells of the innate and adaptive immune system. Contractile, 
quiescent VSMCs can undergo phenotypic transitions and become proliferative, migratory, 
and secrete extracellular matrix. VSMCs may additionally undergo a process of inflammatory 
activation, wherein cells release a diverse range of chemokines and cytokines, take up 
oxidised lipids, and interact with infiltrating immune cells to help propagate inflammation 
and disease. An expanding body of literature continues to report correlative associations 
between pathological VSMC phenotypic modulation, vascular injury or vascular disease 
progression, and reduced expression of myocardin.
17,18,19,20,21
 However, no study to date has 
addressed the question of whether reduced myocardin expression in VSMC is necessary or 
indeed a potentiating factor in the progression of these clinically important phenomena.  
We recently identified myocardin as a critical regulator of the arterial response to wire 
injury.
25
 We now show for the first time that myocardin is a central negative regulator of 
VSMC inflammatory activation and pathological vascular disease. Myocardin 
haploinsufficiency promoted accelerated inflammation and atherosclerosis in 
hypercholesterolemic mice, compared to myocardin-normal controls. VSMCs cultured from 
myocardin-heterozygous-null mice retained a phenotype of reduced myocardin levels and 
increased inflammatory activation potential compared to wild-type controls. Furthermore, 
knockdown of myocardin expression reproduced the effect of increased inflammatory 
activation potential in cultured human coronary artery smooth muscle cells. Conversely, 
raised expression of myocardin in VSMCs potently but specifically suppressed the induction 
of an array of inflammatory cytokines, chemokines and adhesion molecules, while 
upregulating one or more anti-inflammatory mediators. Functionally, expression of 
myocardin in VSMCs reduced oxidised lipid uptake, leukocyte chemotaxis, leukocyte-VSMC 
interaction, leukocyte-endothelial tethering and leukocyte lipid uptake in vitro, and attenuated 
macrophage accumulation within a developing murine lesion in vivo. 
 
Myocardin-null mice die during early development,
13
 and thus cannot be used as a loss-of-
function model in atherosclerosis. However, myocardin-heterozygous-null mice are viable, 
and we recently reported a phenotype of reduced aortic myocardin expression, and 
augmented neointima formation in response to injury with increased SMC migration and 
proliferation.
25
 Our finding that myocardin-heterozygous-null mice exhibit accelerated 
atherogenesis is consistent with the hypothesis that myocardin depletion is a causal factor in 
the pathological VSMC phenotypic transition. Together these studies present a compelling 
demonstration that endogenous levels of myocardin represent a critical regulator of both the 
vessel injury response, and vascular disease. This is corroborated by the in vitro observation 
that VSMCs cultured from myocardin-heterozygous-null aortas retained reduced myocardin 
levels and an increased propensity for inflammatory activation, compared to myocardin wild-
type controls. Similarly increased inflammatory activation in human coronary artery smooth 
muscle cells following siRNA-mediated depletion of myocardin further supports these 
findings and the relevance of myocardin in regulating VSMC inflammatory activation and 
vascular disease in humans. 
Myocardin potently and specifically reduced the production of a diverse range of pro-
inflammatory cytokines, chemokines and adhesion molecules by cultured VSMCs in 
response to IL-1β stimulation. Myocardin strongly inhibited the expression of the 
intracellular pro-inflammatory pathway mediators CEBPB and CEBPD, which are known to 
synergistically upregulate and sustain inflammatory gene expression following SMC 
stimulation.
36,37,38
 Importantly, suppression of these mediators was able to partially reverse 
the increased inflammatory activation in myocardin-deficient VSMCs, suggesting that 
suppression of CEBP factors is a mechanism through which myocardin regulates 
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inflammatory gene expression. That this reversal was only partial, however, implies the 
existence of additional levels of myocardin-mediated inflammatory regulation, possibly 
involving the upregulation of anti-inflammatory mediators IL-19, SOCS-2 and SOCS-6, 
which provide interesting avenues for future research.
 40,41,42 
Of interesting note, the specific 
colony stimulating factor (CSF3) found in our study to be upregulated by myocardin in 
VSMC has been recently linked to decreased plaque area, lipid accumulation and 
macrophage infiltration into atherosclerotic lesions of ApoE
-/-
 mice. 
51
   
A caveat of these experiments is the difficulty of adequately reducing a complex process such 
as atherosclerosis to a basic in vitro model. Much current research analyses cellular responses 
to a single stimulus in culture, whereas cells in vivo are exposed to multiple stimuli 
simultaneously and elicit integrated responses accordingly. Crosstalk between individual 
stimuli can significantly affect the SMC inflammatory phenotype.
7
 Compounding these 
complexities are species differences, and the fact that cells dispersed from organs rarely 
behave as in vivo. In an effort to address some of these issues, the present study demonstrates 
reproducible suppression of a diverse array of VSMC inflammatory responses by myocardin, 
after IL-1β stimulation and presents consistent results using cells isolated from rat, mouse 
and human sources.  
Basic models of VSMC/macrophage and VSMC/EC/macrophage cellular interaction were 
employed to simulate events that occur in a developing lesion, and to assess how increased 
myocardin expression in VSMCs might influence such interactions. Myocardin expression in 
VSMCs was shown to suppress oxidised lipid uptake, macrophage chemotaxis, endothelial 
tethering, VSMC-macrophage interaction and macrophage lipid uptake in vitro. Testing of 
these effects in vivo was performed using a mouse model of lesion-inducing vascular injury.
50
 
Indeed, adenoviral-mediated expression of myocardin in VSMCs significantly reduced 
macrophage accumulation in developing lesions. Together, these data provide compelling 
evidence that myocardin is a central regulator of vascular disease, and furthermore, that 
strategies to prevent or reverse the loss of myocardin expression in VSMCs illustrated in 
schematic Figure 6C, could protect against inflammation, disease onset and progression. 
On the strength of presented and previous evidence,
25
 we propose myocardin as a guardian of 
the quiescent, differentiated, contractile and non-inflammatory VSMC phenotype, with loss 
of myocardin representing a critical permissive step in allowing the process of VSMC 
phenotypic modulation and inflammatory activation to occur at the onset of vascular disease. 
Methods to maintain or increase myocardin expression may protect aortic and coronary artery 
VSMCs from entering dysfunctional programs of synthetic and inflammatory activation. 70% 
of clinical events in patients with coronary artery disease still cannot be prevented with 
modern drug therapy, including statins, emphasising an urgent need for supplementary 
treatment strategies.
52
 Ultimately, myocardin may represent an attractive therapeutic target 
with multiple anti-proliferative, anti-migratory and potent, specific anti-inflammatory 
properties. A future challenge may be to target such therapies specifically to aortic and 
coronary VSMCs, since studies report deleterious effects of increased myocardin expression 
in cerebral VSMCs
53
 and cardiomyocytes
54
. However, successfully tailored myocardin-
activating therapies could overcome problems of individual inflammatory pathway 
redundancy, yet maintain a high degree of VSMC-specificity, thereby reducing off-target, 
undesirable side effects on the immune system as a whole. Further research into the nature of 
VSMC inflammation and the specific mechanisms by which myocardin regulates this process 
will aid in this endeavour, and await exploration. 
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Significance 
 
Cardiovascular diseases are the cause of substantial global mortality and morbidity, and have 
a significant inflammatory basis. Vascular wall smooth muscle cells contribute to disease by 
dividing, migrating into the intimal plaque region, releasing pro-inflammatory mediators, and 
interacting with infiltrating leukocytes. A substantial degree of clinical events in patients with 
vascular disease remain non-preventable with modern drug therapy. We recently identified 
myocardin, a powerful myogenic transcriptional coactivator, as an inhibitor of vascular 
smooth muscle migration after vessel injury. We now demonstrate that myocardin negatively 
regulates vascular smooth muscle inflammation and associated vascular disease, thereby 
revealing the potential of myocardin as an attractive, novel therapeutic target that elicits 
wide-ranging suppression of multiple inflammatory mediators, in addition to anti-
proliferative and anti-migratory effects. We therefore anticipate further important research 
into the nature of vascular smooth muscle cell inflammation in vascular disease, and the 
specific mechanisms by which myocardin regulates this process. 
 
 
Figure Legends 
Figure 1. Loss of myocardin accelerates early atherosclerotic lesion development in a 
murine model of high-fat diet. (A-B) Quantification of myocardin (A) and smooth muscle 
markers, smooth muscle α-actin (Acta2) and smooth muscle myosin heavy chain (Myh11; B) 
mRNA expression in collar-induced atherosclerosis in carotid arteries of ApoE
-/- 
mice (n=3). 
(C-D) Myocardin mRNA expression in normal human aorta and diseased carotid vessels (C; 
n=3) and in SMCs derived from human aorta and diseased carotid plaques (D; n=3). (E) 
Hematoxylin and eosin staining of aortic root sections from ApoE
-/-
.Myocd
+/+ 
(wild type, 
WT) and ApoE
-/-
.Myocd
+/-
 (Myocd
+/-
) mice fed on high-fat diet for 8 weeks. Scale bar, 250 
μm. (F-G) Quantification of aortic root medial (F) and plaque area (G) from WT (n=15) and 
Myocd
+/-
 (n=11) mice fed on high-fat diet. (H) Oil red O staining of aortic root sections from 
WT and Myocd
+/-
 mice fed on high-fat diet for 8 weeks. Scale bar, 250 μm. (I) Quantification 
of lipid rich regions by oil red O staining in the aortic root in WT (n=5) and Myocd
+/-
 (n=6). 
Data are presented as mean±s.e.m. *P<0.05 Student’s t-test. ns indicates no statistical 
significance. 
 
Figure 2. Myocardin haploinsufficiency potentiates infiltration of macrophages and 
inflammation during atherosclerotic lesion development. (A) Confocal images of aortic 
root from high-fat fed ApoE
-/-
.Myocd
+/+ 
(wild type, WT) and ApoE
-/-
.Myocd
+/-
 (Myocd
+/-
) 
mice labelled with antibodies directed against smooth muscle α-actin (ACTA2; green) and 
lysosome-associated membrane protein 2 (LAMP2; red). 4',6-diamidino-2-phenylindole 
(DAPI; blue) counterstaining indicates nuclei. Scale bar, 100 μm. (B) Quantification of 
macrophages (cells positive for LAMP2) in the plaque regions of the aortic root from WT 
(n=5) and Myocd
+/-
 (n=5) mice fed on high-fat diet for 8 weeks. (C) Levels of serum 
monocyte chemotactic protein-1 (CCL2) in WT and Myocd
+/-
 mice fed on high-fat diet for 4 
weeks. Data are presented as a mean fold change relative to week 0. (D) Expression of 
inflammatory marker mRNA in mouse aortic root, after 1 week high fat diet. (E-H) mRNA 
expression of interleukin-6 (Il-6; E),  Ccl2 (F), Cebpb (G) and Cebpd (H) in VSMCs derived 
from WT and Myocd
+/-
 aortas after 4 hr stimulation with interleukin-1beta (IL-1B; n=3). Data 
are presented as mean±s.e.m. *P<0.05, ** P<0.01 and ***P<0.001 Student’s t-test. 
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Figure 3. Myocardin antagonises interleukin-1beta-induced inflammatory pathways in 
vascular smooth muscle cells. (A) Expression of inflammatory marker mRNA in human 
coronary SMC (HCASMC) transfected with scrambled control siRNA or siRNA against 
myocardin (siMYOCD) for 24 hr, before treatment with 20 ng/ml interleukin-1beta (IL-1B). 
(B-C) Release of interleukin-6 (IL-6; B) and monocyte chemotactic protein-1 (CCL2; C) 
from HCASMCs transfected with scrambled control siRNA or siRNA against myocardin 
(siMYOCD), CEBPB (siCEBPB) and CEBPD (siCEBPD), as indicated, for 24 hr, before 
treatment with 20 ng/ml interleukin-1beta (IL-1B). IL-6 and CCL-2 release into surrounding 
media was quantified by enzyme-linked immunosorbent assay (ELISA). Data are presented 
as mean±s.e.m. n=3 independent experiments in biological triplicate. **P<0.01 and 
***P<0.001 compared to scrambled siRNA-only control; #P<0.05 compared to siMYOCD-
only treated cells. Rat aortic VSMCs were then transduced with adenoviral vectors (Ad) 
expressing dominant negative myocardin (Ad.Myocd-DN) control, or myocardin 
(Ad.Myocd). (D) mRNA expression of inflammatory and anti-inflammatory genes 
determined by real time quantitative PCR and presented in a heat map format, for VSMCs 
treated with Ad.Myocd-DN control or Ad.Myocd and stimulated for 4 hr with 20 ng/ml IL-
1B. Red (high) and blue (low) depict differential gene expression relative to mean expression 
across all treatments. Source data are available for this figure (Supplementary Fig 1). (E-F) 
Quantification of IL-6 (E) and CCL2 (F) release after 24 hr IL-1B stimulation. (G-H) Cebpb 
(G) and Cebpd (H) mRNA expression in rat VSMCs treated with Ad.Myocd-DN control or 
Ad.Myocd and stimulated for 4 hr with 20 ng/ml IL-1B. Expression of CEBPB and CEBPD 
in rat VSMCs treated with Ad.LacZ or Ad.Myocd followed by IL-1B stimulation (I). 
Analysis of Il6 and Ccl2 gene promoters by chromatin immunoprecipitation (ChIP) (J). 
VSMCs overexpressing Myocd or Myocd-DN constructs were stimulated for 4 hours with 
IL-1B. Cellular lysates were incubated with anti-CEBPB antibody or IgG antibody (control). 
Bound Il6 and Ccl2 promoter DNA was then quantified by real-time PCR. Data are presented 
as mean±s.e.m, n=3 independent experiments in biological triplicate. *P<0.05, ** P<0.01 
and ***P<0.001 Student’s t-test. ns indicates no statistical significance. 
 
Figure 4. Myocardin reduces the uptake of oxidised lipoproteins. Human coronary 
smooth muscle cells (HCASMCs) were transduced with adenoviral vectors (Ad) expressing 
beta-galactosidase (Ad.LacZ; control) or myocardin (Ad.Myocd) then incubated with Dil-ox-
LDL (10 mg/ml) for indicated time intervals. (A) Effect of myocardin on the uptake of 
fluorescent-labelled oxidised lipoprotein (Dil-ox-LDL; red). 4′,6-diamidino-2-phenylindole 
(DAPI; blue) counterstaining incidates nuclei. Scale bar, 100 m. (B) Quantification of 
accumulated Dil-oxLDL in HCASMCs. Data are presented as mean±s.e.m. ** P<0.01 
Student’s t-test. 
 
Figure 5. Myocardin expression in VSMC reduces macrophage chemotaxis, adhesion 
and uptake of lipids. (A) Myocardin expression in vascular smooth muscle cells (VSMC) 
reduces macrophage chemotaxis. Rat VSMCs were transduced with adenoviral vectors (Ad) 
expressing either dominant negative myocardin (Ad.Myocd-DN) control or myocardin 
(Ad.Myocd) and pre-stimulated for 6 hr with 20 ng/ml interleukin-1beta (IL-1B). 
Fluorescent-labelled RAW264.7 macrophages were applied to upper chambers of coated 
transwell inserts. After 20 hr incubation, un-migrated macrophages on the upper trans-well 
surface were removed and remaining migrated macrophages were quantified. Quantification 
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of fluorescent-labelled macrophages was performed using fluorescence microscopy and 
image analysis with ImageJ software. Data are presented as mean±s.e.m., n=3 independent 
experiments in biological triplicate. *P<0.05 and ** P<0.01 Student’s t-test. (B) Myocardin 
expression in VSMC reduces macrophage adhesion. Confluent VSMC monolayers were 
treated with Ad.Myocd-DN control or Ad.Myocd and pre-stimulated for 24 hr with 20 ng/ml 
IL-1B. VSMC monolayers were incubated for 45 min with fluorescent-labelled RAW264.7 
macrophages, before washing and quantification of adhered macrophages, as above. (C) 
Ad.Myocd-treated VSMCs induce diminished endothelial-macrophage cell interaction. 
Conditioned media was collected from Ad.Myocd-DN (control) or Ad.Myocd transduced, 
unstimulated or IL-1B stimulated VSMCs. Human umbilical vein endothelial cell (HUVEC) 
monolayers were maintained in the conditioned media for 24 hr. The HUVEC monolayers 
were then incubated for 45 min with fluorescent-labelled RAW264.7 macrophages, before 
washing and quantification of adhered macrophages, as above.  (D) VSMCs transduced with 
Ad.Myocd reduce the uptake of acetylated low-density lipoprotein (Ac-LDL) by 
macrophages. Conditioned media was collected from Ad.Myocd-DN (control) or Ad.Myocd 
transduced, unstimulated or IL-1B stimulated VSMCs. RAW264.7 macrophages were 
maintained in the conditioned media for 16 hr. The macrophages were then incubated for 3 
hours with Dil-labelled Ac-LDL (Dil-Ac-LDL; red). Scale bar, 100 m. (E) Quantification of 
Dil-Ac-LDL accumulation in RAW264.7 macrophages. Data are presented as mean±s.e.m., 
n=3 independent experiments in biological triplicate. *P<0.05, ** P<0.01 and ***P<0.001 
Student’s t-test.  
Figure 6. Myocardin inhibits accumulation of macrophages in the neointima. (A) 
Hematoxylin and eosin (H&E) and confocal images of carotid arteries from mice transduced 
with adenoviral vectors expressing beta-galactosidase (Ad.LacZ) control or Ad.Myocd. 
Carotid sections were labelled with antibodies directed against smooth muscle α-actin 
(ACTA2; green) and lysosome-associated membrane protein 2 (LAMP2; red). 4',6-
diamidino-2-phenylindole (DAPI; blue) counterstaining indicates nuclei. Scale bar, 100 m. 
(B) Quantification of macrophages (cells positive for LAMP2) in the neointimal layers. Data 
are presented as mean±s.e.m. *P<0.05 Student’s t-test. Ad.LacZ (n=12) and Ad.Myocd 
(n=13). (C) Schematic illustrating a proposed model whereby reduced myocardin expression 
in contractile medial vascular smooth muscle cells (VSMCs) is a necessary permissive step in 
VSMC inflammatory activation following exposure to atherogenic stimuli, leading to 
increased leukocyte infiltration and progression of atherosclerosis. Dashed arrow represents 
VSMC-independent routes of disease progression. 
 
 






SUPPLEMENTAL MATERIAL 
Materials and Methods 
All chemicals were supplied by Sigma Aldrich (Poole, UK) unless otherwise stated. 
Constructs and vectors 
Adenoviral vectors Ad5.Myocd and Ad5.MyoDN (MyoCΔ381 in Wang et al., 2001) were 
developed in the Owens lab. Ad5.LacZ, Ad5.Myocd, Ad5.MyoDN and Ad5.GFP were 
purchased from the Gene Transfer Vector Core, University of Iowa.  
Primary cell culture 
Aortic VSMCs were isolated from male mouse and Wistar rat aortas by enzymatic 
dissociation as previously described (Geisterfer et al., 1988) and maintained in growth 
medium (Dulbecco’s modified Eagle’s medium (DMEM)/F12 1:1 mix (DF12; Life 
Technologies) supplemented with 10 units/ml penicillin, 10 μg/ml streptomycin, 5 μg/ml L-
glutamine (PSG; Life Technologies) and 10% fetal bovine serum (FBS) (Life Technologies)). 
Cells at 70-80% confluence were serum starved before in vitro experiments, by 24 hr 
incubation in serum-free media (DMEM/F12 supplemented with 1x Insulin-Selenium-
Transferrin (Life Technologies) and PSG). HUVECs were purchased from TCS Cellworks 
(Buckinghamshire, UK) and grown in large vessel endothelial medium + supplements (TCS 
Cellworks). RAW264.7 macrophages were a kind gift from Dr Crystal Mok, Institute of 
Metabolic Science, University of Cambridge. RAW264.7 macrophages were grown on non-
tissue-culture-treated plastic (Starlab) in DMEM supplemented with PSG and heat-treated 
FBS (30 min pre-incubation at 56°C). All cells were grown at 37°C, 5% CO2 and under a 
humidified environment. Human coronary artery smooth muscle cells (HCASMC) were 
purchased from PromoCell and maintained in Smooth Muscle Cell Growth Medium 2 
(PromoCell) supplemented with fetal calf serum (0.05 ml/ml), epidermal growth factor (0.5 
ng/ml), basal fibroblast growth factor (2 ng/ml) and insuli  
Adenoviral transduction 
Cells were administered with adenovirus in a minimal volume of SFM, immediately after 
changing of cell media to SFM in preparation for in vitro experiments as above. Applied viral 
titre was 5 x 10
6
 pfu/ml unless otherwise stated. Cells were then incubated for at least 24 hr in 
SFM before stimulation and/or analysis. 
Western blot analysis 
Whole-cell extracts were prepared by using modified radioimmunoprecipitation assay (RIPA) 
buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Nonidet P-40, 0.25% sodium 
deoxycholate, 1 mM EDTA, protease and phosphatase inhibitor cocktails (Sigma Aldrich, 
UK) and 1 mM NaF. Protein concentrations were determined using a BCA Protein Assay Kit 
(Thermo Scientific). Samples were subjected to sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) separation on 10% gels using Mini-PROTEAN Tetra 
electrophoresis apparatus (Bio-Rad) and transferred onto polyvinylidene difluoride (PVDF) 
membranes. Membranes were blocked in 5% milk in Tris-buffered saline and 0.05% Tween 
20 (TBS-T) and incubated with primary antibodies as detailed in Supplementary Table 1, 
followed by incubation with horseradish peroxidase-conjugated secondary antibodies (Dako). 
Signals were detected using enhanced chemiluminescence detection reagents (ECL; GE 
Healthcare). 
RNA extraction, reverse-transcription PCR and quantitative real time PCR 
Total RNA was prepared from cultured cells using TRIzol (Life Technologies) according to 
manufacturer's protocol. For tissue analysis, tissues were first homogenised in TRIzol using 
Polytron apparatus. cDNA was synthesised using Maxima First Strand cDNA Synthesis Kit 
(Thermo Scientific). QPCR analysis was conducted using gene-specific primers, SYBR 
GreenER Real-Time PCR Master Mix (Life Technologies) and Corbett Rotor-Gene 6000 
apparatus and software. mRNA levels are expressed relative to 18S and GAPDH 
housekeeping gene controls, except Fig. 1, A and B, measured relative to murine 
hypoxanthine phosphoribosyltransferase (Hprt). Oligonucleotide primers were designed 
using PrimerBLAST (NCBI) and are listed in Supplemental Table II.  Software for building 
the gene expression heat map was developed and generously made available by Dr Euan 
Ashley, School of Medicine, Stanford University 
(http://ashleylab.stanford.edu/tools_scripts.html)  
Chromatin Immunoprecipitation Assays (ChIP) 
Rat VSMCs (1 x 10
6
) were transduced with Ad.LacZ or Ad.Myocardin for 8 h. The virus was 
removed and cells were allowed to recover for further 24 h. Cells were fixed in formaldehyde 
for 15 min, lysed, and sonicated. The cell lysates were immunoprecipitated by incubation 
with either IgG (Sigma) or CEBPB (Abcam) antibodies overnight. Formaldehyde 
crosslinking was reversed by incubation with 200 mM NaCl, overnight at 65°C and protein 
was degraded by further incubation with proteinase K (Thermo Scientific) overnight at 45°C. 
DNA was then isolated by phenol-chloroform extraction and ethanol precipitation, and 
quantified by quantitative PCR using specific promoter-targeted primers (Supplementary 
Table II). 
Inflammatory induction experiments using cultured rodent VSMCs 
VSMCs were seeded at 1 x 10
4
 cm
-2
 into 12-well tissue-culture treated plates (Starlab) in 
normal growth medium. After 24 hr, media was removed, cells were washed once in SFM 
and incubated in fresh SFM. Where appropriate, adenoviruses were administered in minimal 
volumes of SFM. After a further period of incubation (24 hr unless otherwise stated), SFM 
was changed and inflammatory stimulants were applied (20 ng/ml or variable IL-1β 
(Peprotech, London); 10 ng/ml TNFα (Peprotech), 1 μg/ml LPS (Sigma) or vehicle-only 
control (0.1% BSA in PBS). Cells were incubated with stimulants for stated time periods 
before removal, centrifugation (1000 g, 10 min, 4°C) and analysis of media by ELISA 
(Peprotech) according to manufacturer’s instructions. Cellular material was processed and 
analysed by Western blot or RT-QPCR, as described above. 
Inflammatory induction experiments using cultured human coronary artery smooth 
muscle cells (HCASMC) 
HCASMC were seeded onto 12-well tissue-culture treated plates (Starlab) in Smooth Muscle 
Cell Growth Medium 2. After 24 hr, the cells were transfected with mixture of 4 MYOCD 
siRNAs (ON-TARGETplus – SMARTpool; Thermo Scientific) or control scrambled siRNA 
using DharmaFECT reagent (Thermo Scientific). The siMYOCD target sequences are a) 
GGUUUACACUCUUCUGAUA, b) GGAAUAACUGUUCAGAGAA, c) 
GUGCCGACUUGGUUAAUAU, d) GAUAAUGGAUGGAUUCUCU. After 8 hours of 
transfection, cells were washed and maintained in SFM for 18 hours. Cells were treated with 
IL-1β (20 ng/ml; Peprotech, London) for 6 hr for mRNA analysis and 24 hr for cytokine 
measurements. 
VSMC immunocytochemistry 
Plated VSMCs were fixed in 4% paraformaldehyde, permeabilised with 0.5% Triton-X, and 
incubated for 1 hr in blocking solution (3% bovine serum albumin (BSA) plus 5% serum 
derived from the same species as the secondary antibody (Dako), in phosphate buffered saline 
(PBS)). Cells were then incubated with primary antibody in blocking solution for 16 hr, at 
4°C. Specific staining was subsequently detected using standard fluorescent microscopy 
(Olympus) following 1 hr incubation with fluorescent-conjugated secondary antibody in 
PBS+0.1% BSA. Antibody details are given in Supplemental Table I. 
Lipid uptake assay 
Human Coronary Smooth Muscle Cells (HCASMCs) were transduced with Ad5.Laz or 
Ad5.Myocd for 48 hr and then incubated with Dil-labelled oxidised LDL (Dil-Ox-LDL; 
Biomedical Technologies, BT-920, 10 ug/ml) or in growth medium for 2 hr or 3 hr. Cells 
were immediately fixed with 3% formaldehyde for 20 min and counterstained with DAPI for 
5 min. Red fluorescent staining shows the Ox-LDL uptake and quantitative data were 
analysed by Image J.  
VSMC-macrophage adhesion assay 
Using 12-well tissue-culture-treated plates (Starlab), VSMC monolayers were grown to 
confluence in cell growth media, before changing to SFM and administration of adenoviral 
constructs where appropriate, and 24 hr incubation. Cells were then further incubated for 24 
hr in the presence of 20 ng/ml IL-1β. Concurrently, near-confluent RAW264.7 macrophages 
were administered with Qdot 655 ITK carboxyl quantum dots (Life technologies) at 8 nM 
final concentration, and incubated for 24 hr in normal growth media. These RAW264.7 
macrophages were then gently washed twice in SFM before resuspension of the cells, now 
marked with the Qdot particles, in fresh SFM. Cell titre was measured by haemocytometer 
and adjusted to 2 x 10
5
 cells/ml. VSMC monolayers were then washed in SFM and incubated 
for 45 min with 1 x 10
5
 (500 μl) Qdot-labelled RAW264.7 macrophages, before further 
washing and examination of macrophage adherence by fluorescence microscopy. 
Quantification was performed by particle analysis of fluorescent images using ImageJ 
software (National Institutes of Health). 
EC-macrophage adhesion assay 
VSMCs were treated as described in the inflammatory activation experiment protocol as 
above, with administration of either MyoDN control or Myocd adenoviral constructs, before 
treatment with 20 ng/ml IL-1β or vehicle control for 8 hr. Cells were then washed twice with 
SFM to remove IL-1β, and fresh SFM was added and incubated for a further 16 hr. This 
media was then centrifuged (1000 g, 10 min, 4°C), sterile-filtered with 0.2 μm filters 
(Millipore) and collected as VSMC conditioned media. Using 12-well tissue-culture-treated 
plates (Starlab), Human umbilical vein endothelial cell (HUVEC) monolayers were grown to 
confluence in HUVEC cell growth media. Cells were washed in SFM and VSMC conditioned 
media was applied and incubated for 24 hr, and Qdot-labelled RAW264.7 macrophages were 
prepared as previously. HUVEC monolayers were washed and treated with Qdot-labelled 
RAW264.7 cells as described above, and fluorescent microscopy with image analysis using 
ImageJ was used to quantify macrophage adhesion to the HUVEC monolayers. 
Macrophage migration trans-well assays 
VSMCs were treated as described in the inflammatory activation experiment protocol as 
above, with administration of either MyoDN control or Myocd adenoviral constructs, and 24 
hr incubation.  12-well plate sized trans-well insert membranes with 8 μm pores (Sigma) 
were pre-coated by incubation with 10 μg/ml fibronectin (Sigma) in PBS for 24 hr at 4°C. 
Qdot-labelled RAW264.7 macrophages were prepared as previously. VSMCS were then 
administered with 20 ng/ml IL-1β or vehicle control for 6 hr. Cells were then washed twice 
with SFM to remove IL-1β, and fresh SFM was added and incubated for a further 12 hr. The 
pre-coated trans-well inserts were then applied and filled with 2 ml SFM containing 2 x 10
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cells of labelled RAW264.7 macrophages in suspension. After a further 20 hr incubation, 
trans-well inserts were taken, emptied, and un-migrated macrophages on the upper membrane 
surface were removed by gentle rubbing with a cotton bud, and further washing in PBS. 
Migrated Qdot-labelled RAW264.7 macrophages were quantified by fluorescence 
microscopy and analysis using ImageJ. 
Macrophage LDL uptake Assay 
VSMCs were treated as described in the inflammatory activation experiment protocol as 
above, with administration of either MyoDN control or Myocd adenoviral constructs, before 
treatment with 20 ng/ml IL-1β or vehicle control for 8 hr. Cells were then washed twice with 
SFM to remove IL-1β, and fresh SFM was added and incubated for a further 16 hr. This 
media was then centrifuged (1000 g, 10 min, 4°C), sterile-filtered with 0.2 μm filters 
(Millipore) and collected as VSMC conditioned media. Using 12-well tissue-culture-treated 
plates (Starlab), RAW264.7 macrophages were grown to confluence in DMEM growth 
media. Cells were washed in SFM and VSMC conditioned media was applied and incubated 
for 16 hr. The macrophages were then incubated for 3 hours with 10 ug/ml Dil-labelled 
Acetylated-LDL (Dil-Ac-LDL; Life Technologies). After 3 hours the macrophages were 
washed with PBS and nuclei counter-stained with DAPI. Cells were imaged using a Zeiss 
LSM 700 Laser Scanning Microscope. The red intensity was calculated by using ImageJ 
software. 
Human arterial and VSMC samples 
Healthy human arterial samples were obtained from normal aortas of patients undergoing 
cardiac transplantation. Carotid endarterectomy samples were used to provide diseased vessel 
samples. These tissues were first homogenised in TRIzol (Life Technologies) and total RNA 
was then prepared according to manufacturer's protocol. Alternatively, human VSMCs were 
cultured using an explant method from these healthy and diseased samples (Kavurma et al., 
2008). The endothelial layer was removed using a scalpel and tissue cut into small pieces 
(approximately 2-3mm²), placed into 6-well plates containing 1ml media (DMEM containing 
10% FBS, L-glutamine and P/S) and grown for 1-2 weeks to allow cells to emerge. 
Experiments were performed at cell passage number 2-5. Full informed consent and Local 
Ethics Committee approval were obtained.  
Mouse model of non-constrictive collar-induced atherosclerosis 
Animal work was approved by the regulatory authority of Leiden University and performed 
in compliance with Dutch government guidelines. Male LDLr
−/−
 mice were obtained from the 
Jackson Laboratory and bred in a local animal breeding facility. Mice were fed a high-fat diet 
containing 0.25% cholesterol and 15% cacaobutter (Special Diet Services, Sussex, UK) two 
weeks before surgery and throughout the experiment. To determine the gene expression 
levels in mouse plaques (n = 20), atherosclerotic carotid artery lesions were induced by 
perivascular collar placement as described previously (von der Thüsen et al., 2001). Gene 
expression profiles of carotid artery plaques were determined at 0 to 10 weeks after 
perivascular collar placement. Subsets of four mice were sacrificed by perfusion through the 
left cardiac ventricle with phosphate-buffered saline (PBS). Subsequently, both common 
carotid arteries were excised, snap-frozen in liquid nitrogen for optimal RNA preservation, 
and stored at −80°C until further use. Two to three carotid artery segments carrying the 
plaque from 0, 2, 4, 6, 8 or 10 weeks after collar placement were pooled for each sample and 
homogenized by grounding in liquid nitrogen with a pestle (Bot et al., 2010). Total RNA was 
extracted from the tissue homogenates using Trizol reagent according to manufacturer’s 
instructions (Invitrogen, Breda, The Netherlands).  
Mouse model of high fat diet-induced atherosclerosis 
Myocardin heterozygous-null 129/C57BL/6 mixed background (Myocd
+/-
) mice were a kind 
gift from Prof. Olson (Li et al., 2003). Myocd
+/-
 mice were crossed twice with ApoE
-/-
 males 
(C57BL/6 background) to produce offspring with the genotype ApoE
-/-
.Myocd
+/-
. Breeding 
pairs were then selected consisting of ApoE
-/-
.Myocd
+/-
 females (mixed background) and 
ApoE
-/-
 males (C57BL/6 background). From subsequent offspring, ApoE
-/-
.Myocd
+/-
 male 
(n=11) and age-matched ApoE
-/-
.Myocd
+/+
 littermate control (n=15) groups were selected. 
These mice were then fed a high fat diet for 8 weeks, before euthanisation, pressure perfusion 
fixation and embedding of aortas in paraffin for histological analysis. Blood samples from 
each mouse taken at point of sacrifice were analysed for specified lipid and inflammatory 
marker content by the Core Biochemical Assay Laboratory, Addenbrooke’s site, University 
of Cambridge. These animal experiments were performed with ethical approval from the 
University of Cambridge ethical review panel, and under UK Home Office licensing. 
Mouse model of carotid artery wire injury 
Animal surgery was undertaken in compliance with the University of Leiden and Dutch 
government guidelines. Transluminal arterial injury was induced as previously described 
(Krohn et al., 2007; Talasila et al., 2013) in 8-week old ApoE
-/-
 mice (C57BL/6 background) 
fed with a western diet for 1 week before and for 4 weeks post-injury. Mice were 
anaesthetised using subcutaneous injection of ketamine (60 mg/kg; Eurovet Animal Health, 
The Netherlands) and hypnorm (5%; VetaPharma, UK). Wire injury was induced with a 0.36-
mm flexible angioplasty guide-wire by transverse arteriotomy of the external carotid artery. 
The endothelial layer was denuded by 3 rotational passes. Immediately after injury, the left 
common carotid artery was cannulated and the biclamped segment incubated with 10 µl of 
either Ad5.LacZ control or Ad5.Myocd adenoviral constructs at 1.5 x 10
10
 pfu/ml (n=14 per 
group) for 20 min. Post viral transduction, the left external carotid was ligated but flow was 
restored to the left internal carotid artery. After recovery and 28 days high-fat diet, animals 
were sacrificed and pressure-perfused with 10% formalin and vessels embedded in paraffin 
for morphometric and histological analysis. Animals were excluded from analysis if they died 
prematurely, if there was no injury response or if the injured vessel was totally occluded at 
time of harvest (Talasila et al., 2013).  
Histology and Immunohistochemistry 
For the wire injury model, carotid arteries were cut into 3 pieces of identical length, and 
multiple 5 µm sections at 225 µm intervals were taken in order to ensure coverage of the 
injured region. For the atherosclerosis model, aortic root was cut with 5 μm serial sections. 
Sections were deparaffinated and stained with haematoxylin and eosin (H&E). H&E section 
images were captured using a BX51 microscope (Olympus) and intima/media area 
measurements were quantified using Cell^D software (Olympus). For 
immunohistochemistry, antigen retrieval was achieved by boiling in sodium citrate buffer (10 
mM sodium citrate acid, 0.05% Tween 20, pH 6.0). Double immuno-fluorescence staining 
used antibodies to ACTA2 (FITC-conjugated) and LAMP2 or CD68 using an Alexa Fluor-
568 conjugated secondary antibody. Antibody details are listed in Supplemental Table I. 
Coverslips were mounted using Vectashield with 4',6-diamidino-2-phenylindole (DAPI). 
Cells were imaged using a Zeiss LSM 700 Laser Scanning Microscope. Morphometric 
analysis and cell counting were performed while blinded to treatment groups. 
Oil Red O Staining 
Aortic root cryosections (10 µm) were stained with oil red O and 12 sections spanning the 
entire aortic root (every 70 µm) were imaged and quantified using a Leica DM6000 
microscope and LAS AF software. 
Statistical Analysis 
Data are representative of at least two independent experiments and were conducted in 
biological triplicates, unless otherwise stated. Data are presented as mean ± s.e.m. (standard 
error of the mean). Differences between group means were examined using two-tailed, 
unpaired Student’s t-test or using One Way Analysis of Variance (ANOVA) with Bonferroni 
test, and were accepted as significant when P<0.05. Statistical tests were performed using 
GraphPad Prism (GraphPad Software, San Diego, CA). 
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Supplemental Table I: List of antibodies. 
Antibody Application    Concentration Source Manufacturer 
(Catalogue number) 
ACTB Western Blotting 1:10,000 Mouse  Sigma-Aldrich (A1978) 
CCL2 Immunofluorescence 1:75 Mouse Thermo Scientific (MA5-
17040) 
CD68 Immunofluorescence 1:75 Rat Serotec (MCA1957) 
CEBPB Western Blotting 
ChIP 
1:1000 
4 μg 
Rabbit Abcam (ab32358) 
CEBPD Western Blotting 
ChIP 
1:200 
4 μg 
Rabbit Santa Cruz (sc-151) 
CEBPD ChIP 4 μg Rabbit Abcam (ab65081) 
CNN1 Immunofluorescence 1:30,000 Mouse Sigma-Aldrich (C2687) 
LAMP2 Immunofluorescence 1:200 Rat BD Pharmingen 
(M3/84) 
MYOCD Western Blotting 1:1000 Mouse Sigma-Aldrich (M8948) 
Smooth 
muscle- 
Actin 
conjugated to 
FITC 
Immunofluorescence 1:200 Mouse Sigma-Aldrich (F3777) 
TAGLN Immunofluorescence 1:200 Rabbit Abcam (ab14106) 
 
 
 
 
 
 
  
Supplemental Table II: List of Primers used in real time PCR 
Gene            Primer Sequence 
18S (Human) 
 
18S (Mouse) 
 
18S (Rat) 
GACACGGACAGGATTGACAGATTG 
TGCCAGAGTCTCGTTCGTTATCG 
TTGACGGAAGGGCACCACCAG 
GCACCACCACCCACGGAATCG 
ATTGACGGAAGGGCACCACCAG 
AAGAACGGCCATGCACCACCAC 
 
36B4 (Mouse)  GGACCCGAGAAGACCTCCTT 
 GCACATCACTCAGAATTTCAATGG 
Acta2 (Rat)  AGTCGCCATCAGGAACCTCGAG  
 ATCTTTTCGATGTCGTCCCAGTTG 
CCL2 (Human) 
Ccl2 (Mouse) 
Ccl2 (Rat) 
 AAGCTCGCACTCTCGCCTCCA 
 GCATTGATTGCATCTGGCTGAGCG 
 GCCTGCTGTTCACAGTTGCCG 
 ACCCATTCCTTCTTGGGGTCAGC 
 GGTCTCTGTCACGCTTCTGGGC 
 TGGGGCATTAACTGCATCTGGCTGA 
CEBPB (Human) 
Cebpb (Mouse, Rat) 
ATGTTCCTACGGGCTTGTTG 
CCCAAAAGGCTTTGTAACCA 
AAGCTGAGCGACGAGTACAAG 
AGCTGCTCCACCTTCTTCTG   
 
CEBPD (Human) 
Cebpd (Mouse) 
Cebpd (Rat) 
CAGCAACGACCCATACCTCA 
TCTTTGCGCTCCTATGTCCC 
CCAGGCAGGGTGGACAAG 
CGCTTTGTGGTTGCTGTTGA 
AAGCTGCATCAGCGTGTG 
CAGTCCAGTGCCCAAGAAAC 
 
Csf1 (M-csf; Rat)  GAGGTGTCGGAGCACTGTAG 
 GTAGCAAACGGGATCGTCCA 
Csf3 (G-csf; Rat)  TCTGCTCAAGGACGCATGAA 
 CAGAAAGCTTCGGGGCAAAG 
Cx3cl1(Rat)  CTCCCTCACAGCTCGCGTGG  
 AGGATGATGGCGCGCTTGCC 
Cxcl2 (Rat) CACTCTTTGGTCCAGAGCCAT 
GGTAGGGTCGTCAGGCATTG 
GAPDH (Mouse, Rat, Human) GCTGCGTTTTACACCCTTTC 
GTTTGCTCCAACCAACTGC 
 
Icam1 (Rat)  TCCTGGTCCTGGTCGCCGTT 
 ACCCCGAGGCAGGAAGGCTT 
Il-19 (Rat)  ACAGTGCGCGTCTCGATGGC 
 GCAGGTTGTTGGTCACGCAGC 
Il-1r1 (Rat)  TGTGCCTCTGCTGTCGCTGG 
 TGGTGCCGCCATGCATTTCG 
IL-6 (Human) 
Il-6 (Mouse) 
Il-6 (Rat) 
 AAATTCGGTACATCCTCGACGG 
 GGAAGGTTCAGGTTGTTTTCTGC 
 AGACAAAGCCAGAGTCCTTCAGAGA 
 GCCACTCCTTCTGTGACTCCAGC 
 TGATGGATGCTTCCAAACTG 
 GGTTTCAGTATTGCTCTGAATGAC  
Il-6r (Rat)  GCGCTGGTCCTTGGGAGCTG 
 GCTTGGGCTCCTCTGGGGGA 
Myh11 (Rat) CAGTTGGACACTATGTCAGGGAAA 
ATGGAGACAAATGCTAATCAGCC 
MYOCD (Human) 
Myocd (Mouse) 
Myocd (Rat) 
 TGCAGCTCCAAATCCTCAGC 
 TCAGTGGCGTTGAAGAAGAGTT 
 AAACCAGGCCCCCTCCC 
 CGGATTCGAAGCTGTTGTCTT 
 AAACCAGGCCCCCTTCC 
 CGGATTCGAAGCTGTTGTCTT 
Nos2 (Rat)   AGGCTCACGGTCAAGATCC 
  CCATGTACCAACCATTGAAGG 
Olr1 (Rat) GTGGTGCCCTGCTGCTGTGA 
CTGGGCTGACATCTGCCCCTCC 
Socs1 (Rat) CGGCCAGAGCCATCCTCGTC 
GAGCGCTGGTCCGCGTGATG 
Socs2 (Rat) GGAATGGCGCGGACAGGACAC 
TCGGCCCGGCTGATGTCTTAACAG 
Socs3 (Rat) ACCCAGCTGCCTGGACCCATT 
CTCGGAGGAGAGGCGACCGA 
Socs4 (Rat) GTCCCTCGGACAGCTCCGGT 
TCCGACTTGTTTTAGGCCGCACA 
Socs5 (Rat) TGGATCCGCCGGGAAGAGGA 
TCGCCCAGACTGACGCTTTTCTC 
Socs6 (Rat) CATGCTGCCAGCCCAGGACC 
CGATTACTACAGGCACGTGCTCCTC 
Tagln (Rat GCATAAGAGGGAGTTCACAGACA  
GCCTTCCCTTTCTAACTGATGATC 
Tnfr1a (Rat) TGAGTGCACCCCTTGCAGCC 
AACCAGAGGCAACAGCACGGC 
Vcam1 (Rat) ATGGTCGCGATCTTCGGAGCC 
AACGGACTTGGCCCCCTCTGT 
Il-6 promoter (ChIP; Fig. 3J) ACACACTTTCCCCCTCCTAGCTG 
TTCGTTCCTGGTGGGCTCGA 
Ccl2 promoter (ChIP; Fig. 3J) CAGACTATGCCTTTGTTGAGCTATT 
GCAGAGTAGGATAAGAGTGTGGAAA 
Ccl2 promoter Region 1 
(Supplementary Figure XII) 
CAGCTTCATTTGCTCCCAGTAGT 
AAGTTTGAATCTGCTGAGTAAGTGC 
Ccl2 promoter Region 2 
(Supplementary Figure XII) 
AAACAGCTCATATCAATGTCACAAG 
TTAGTCCACTGAGTCCTTGGTTATC 
Ccl2 promoter Region 3 CAGACTATGCCTTTGTTGAGCTATT 
(Supplementary Figure XII) GCAGAGTAGGATAAGAGTGTGGAAA 
Ccl2 promoter Region 4 
(Supplementary Figure XII) 
TAGAAAGCTCACCATCACTTCTTCT 
GCAATGGAAAGTTTTTCTGAGTTAT 
Ccl2 promoter Region 5 
(Supplementary Figure XII) 
TCTTATACTGGTGGTAGCTGCTCTT 
GGCTATGAGTTTTCTCTGTGTTCTC 
 
 
 
 
 
1Supplementary Figure I. Expression of myocardin in the in vivo and in vitro models used in the
study.
(A) Myocardin heterozygous-null mice aortic tissue lysates were analysed by Western blotting using
antibodies against myocardin (MYOCD), myocardin-related transcription factor A (MKL1), myocardin-
related transcription factor B (MKL2), and -actin (ACTB). (B) -galactosidase expression in medial
layers of the injured carotid artery. Carotid artery was stained for -galactosidase expression (blue) 5
days following wire injury and transluminal infection of Ad.LacZ. Scale bar: 100 m.
Note, Suppl. Figure IA and IB were reproduced from our previous published work (Talasila A, Yu H,
Ackers-Johnson M, Bot M, van Berkel T, Bennett MR, Bot I, Sinha S. 2013. Myocardin Regulates
Vascular Response to Injury Through miR-24/-29a and Platelet-Derived Growth Factor Receptor-β.
Arterioscler Thromb Vasc Biol 33:2355-65)
(C) Adenoviral transfection efficiency in rat vascular smooth muscle cells. Adenoviral-expressed Myocd
and Myocd-DN proteins in this study carried a FLAG-tag. Total cell lysates underwent Western blotting
using antibodies against FLAG. (D) Myocardin expression in rat vascular smooth muscle cells post-
Ad.Myocd transfection.
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2Supplementary Figure II. Myocardin haploinsufficiency promotes early atherosclerotic lesion
development in a murine model of high-fat diet.
(A) Hematoxylin and eosin staining of aortic root sections from ApoE-/-.Myocd+/+ (wild type, WT) and
ApoE-/-.Myocd+/- (Myocd+/-) mice fed on high-fat diet for 8 weeks. Scale bar, 250 μm. (B) 20x
magnification of a representative intima shoulder region. An individual ACTA2-positive VSMC (green,
white triangle) and a LAMP-2-positive macrophage (red; white arrow), are indicated as examples. (C)
Mouse serum analysis. Blood was taken from ApoE-/-.Myocd+/- mice and ApoE-/-.Myocd+/+ littermate
controls at the point of euthanisation following 8 week high fat diet. Blood serum was analysed for lipid
content, as indicated. Data are presented as mean±s.e.m. No significant differences between ApoE-/-
.Myocd+/- mice and ApoE-/-.Myocd+/+ littermate controls were observed.
C
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3Supplementary Figure III. Non-specific labelling of myocardium.
Confocal images of aortic root from high-fat fed ApoE-/-.Myocd+/+mice labelled with antibodies directed
against smooth muscle α-actin (ACTA2; green) and IgG (red). 4',6-diamidino-2-phenylindole (DAPI;
blue) counterstaining indicates nuclei. In the IgG panel, myocardium is outlined with a green square.
Scale bar, 100 μm.
Nuclei ACTA2 IgG Overlay
ACTA2 IgG OverlayNuclei
4Supplementary Figure IV. Myocardin haploinsufficiency potentiates infiltration of
macrophages and inflammation during atherosclerotic lesion development.
(A) Confocal images of aortic root from high-fat fed ApoE-/-.Myocd+/+ (wild type, WT) and ApoE-/-
.Myocd+/- (Myocd+/-) mice for 8 weeks labelled with antibodies directed against smooth muscle α-actin
(ACTA2; green) and CD68 (red). 4',6-diamidino-2-phenylindole (DAPI; blue) counterstaining indicates
nuclei. Scale bar, 100 μm. Quantification of CD68+ and ACTA2- cells in the plaque layer (B). Data are
presented as mean±s.e.m. **P<0.01
WT
Myocd+/-
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5Supplementary Figure V. Enhanced CCL2 expression was observed in myocardin
haploinsufficiency mice post-high fat diet.
(A) Confocal images of aortic root from high-fat fed ApoE-/-.Myocd+/+ (wild type, WT) and ApoE-/-
.Myocd+/- (Myocd+/-) mice for 8 weeks labelled with antibodies directed against smooth muscle α-actin
(ACTA2; green) and monocyte chemotactic protein (CCL2; red). 4',6-diamidino-2-phenylindole (DAPI;
blue) counterstaining indicates nuclei. Scale bar, 100 μm. Quantification of CCL2 levels in medial (B)
and plaque (C) layers. CCL2 expression is calculated by the total red pixel intensity using ImageJ
software analysis. Data are presented as mean±s.e.m. *P<0.05, ns – not significant
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Myocd+/-
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6Supplementary Figure VI. mRNA expression of myocardin, CEBPB and CEPBD in human
coronary SMC (HCASMC).
HCASMC were transfected with scrambled control siRNA or siRNA against myocardin (siMYOCD),
CEBPB (siCEBPB) and CEBPD (siCEBPD) for 24 hr. RNA expression is shown relative to levels
expressed in HCASMC transfected with control siRNA. Data are presented as mean±s.e.m., n=2-3.
7Supplementary Figure VII. Increased contractile marker gene expression in VSMCs transduced
with Ad.Myocd.
(A-B) Rat VSMCs were transduced with adenoviral constructs as indicated. (A) Quantification of
myocardin (Myocd) and SMC marker gene mRNA in VSMCs, 24 hr post-transduction. Acta2, smooth
muscle alpha-actin; Tagln, transgelin; Myh11, smooth muscle myosin heavy chain. Note: Myocd primers
utilised in this work do not detect Myocd-DN. (B) SMC marker gene expression in transduced rat
VSMCs detected by immunocytochemistry. CNN1, smooth muscle calponin. Fluorescent images were
captured at 20x magnification. (C) Time-course of Myocd and Myh11 expression in rat VSMC after
transduction with Ad.Myocd.  Data are presented as mean±s.e.m., and are representative of at least three
separate experiments in biological triplicate. *P<0.05; **P<0.01 Student’s t-test. n=3.
A
B
C
8Supplementary Figure VIII. Myocardin
expression in cultured VSMC suppresses diverse
pro-inflammatory responses and enhances
production of specific anti-inflammatory
mediators.
Rat VSMCs were seeded, transduced with
adenoviral constructs and stimulated for 4 hr with
20 ng/ml interleukin-1beta (IL-1β). RNA was
harvested and expression of a selection of
inflammatory-related mediators was analysed by
real time quantitative PCR, as indicated. Data are
presented as mean±s.e.m., and are representative of
at least three separate experiments in biological
triplicate. *P<0.05; **P<0.01; ***P<0.001
Student’s t-test.
9Supplementary Figure IX. Overexpression of Myocd-DN has no effect on human coronary artery
smooth muscle cells (HCASMC)
HCASMC were seeded, transduced with adenoviral constructs and stimulated for 4 hr with 20 ng/ml
interleukin-1beta (IL-1β). RNA was harvested and expression of a selection of smooth muscle marker
genes and inflammatory-related mediators was analysed by real time quantitative PCR, as indicated.
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Supplementary Figure X. Myocardin inhibits pro-inflammatory responses in human
coronary artery smooth muscle cells (HCASMC)
HCASMC were seeded, transduced with adenoviral constructs and stimulated for 4 hr with
20 ng/ml interleukin-1beta (IL-1β). (A) RNA was harvested and expression of a selection of
inflammatory-related mediators was analysed by real time quantitative PCR, as indicated. (B-
C) Quantification of IL-6 (B) and CCL2 (C) release after 24 hr IL-1β stimulation. Data are
presented as mean±s.e.m., and are representative of at least three separate experiments.
*P<0.05; **P<0.01 Student’s t-test.
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Supplementary Figure XI. Myocardin suppresses secretion of inflammatory mediators from
VSMCs in response to a variety of stimuli.
Rat VSMCs were seeded, transduced with adenoviral constructs and stimulated with pro-inflammatory
factors as indicated. Media were collected after 24 hr inflammatory stimulation and analyzed by ELISA.
A-D Interleukin-6 (IL-6) release (pg/ml) from transduced VSMCs stimulated with (A) 20 ng/ml
interleukin-1beta (IL-1β), (B) 10 ng/ml tumour necrosis factor alpha (TNFα), (C) 1 μg/ml bacterial
lipopolysaccharide (LPS), and (D) monocyte chemotactic protein-1 (CCL2) release from transduced
VSMCs stimulated with 20 ng/ml IL-1β. (E) VSMCs were transduced with adenoviral constructs at
varying multiplicity of infection (MOI) as indicated, before 24 hr incubation with 20 ng/ml IL-1β. Arrow
indicates the standard viral MOI (150) corresponding to 5 x 106 pfu/ml. CCL2 release was measured by
ELISA. Data are presented as mean±s.e.m., and are representative of at least three separate experiments
in biological triplicate. *P<0.05; **P<0.01 Student’s t-test.
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Supplementary Figure XII. Chromatin immunoprecipitation analysis at Ccl2 gene promoter regions.
Rat VSMCs overexpressing Myocd or Myocd-DN constructs were stimulated for 4 hours with interleukin-
1beta (IL-1β). Cellular lysates were incubated with anti-CEBPD antibody or IgG antibody (control). Bound
DNA at five different regions of the Ccl2 promoter was then quantified by real-time PCR.
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Supplementary Figure XIII. Testing the functional effects of myocardin expression in VSMC on
macrophage recruitment and interaction. (A-B), Schematic diagrams depicting (A) macrophage migration
trans-well assay and (B) macrophage-endothelial cell interaction assay. (C) Fluorescent labelled macrophages
attaching to a VSMC monolayer (20x magnification)
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Supplementary Figure XIV: Myocardin expression in HCASMC reduces macrophages chemotaxis
and adherence. (A) Myocardin expression in human coronary artery SMCs (HCASMCs) reduces
macrophage chemotaxis in vitro. HCASMCs were transduced with adenoviral vectors (Ad) expressing
either dominant negative myocardin (Ad.Myocd-DN) control or myocardin (Ad.Myocd) and pre-
stimulated for 6 hr with 20 ng/ml interleukin-1beta (IL-1β). Fluorescent-labelled RAW264.7
macrophages were applied to upper chambers of coated transwell inserts. After 20 hr incubation, un-
migrated macrophages on the upper trans-well surface were removed and remaining migrated
macrophages were quantified. Quantification of fluorescent-labelled macrophages was performed using
fluorescence microscopy and image analysis with ImageJ software. Data are presented as mean±s.e.m.,
n=2 independent experiments in biological triplicate. *P<0.05 and ** P<0.01 Student’s t-test. (B)
Myocardin expression in HCASMCs reduces macrophage adhesion in vitro. Confluent VSMC
monolayers were treated with Ad.Myocd-DN control or Ad.Myocd and pre-stimulated for 24 hr with 20
ng/ml IL-1β. VSMC monolayers were incubated for 45 min with fluorescent-labelled RAW264.7
macrophages, before washing and quantification of adhered macrophages, as above.
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